Mexiprim, 50 mg/ml 5 ml 15 pcs

Mexiprim belongs to the heteroaromatic antioxidants.

It has a wide range of pharmacological activity: increases the body’s resistance to stress, shows anxiolytic effect, not accompanied by drowsiness and myorelaxant effect; has nootropic properties, prevents and reduces learning and memory disorders arising from aging and exposure to various pathogenic factors; has anticonvulsant effect; shows antioxidant and antihypoxic properties; increases attention concentration and performance; weakens the toxic effects of alcohol.

The drug improves brain tissue metabolism and blood supply, improves microcirculation and blood rheology, reduces platelet aggregation.

Stabilizes membrane structures of blood cells (erythrocytes and platelets). It has hypolipidemic effect, decreases the total cholesterol and low-density lipoproteins.

Mechanism of action of Mexiprim is due to its antioxidant and membrane-protective effect.

It inhibits lipid peroxidation, increases superoxidase activity, increases lipid-protein ratio, decreases membrane viscosity and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine) that increases their ability to bind to ligands, maintains structural and functional organization of biomembranes, neurotransport and improves synaptic transmission.

Mexiprim increases dopamine content in the brain.

Causes compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Pharmacokinetics

Maximum concentration of Mexiprim in plasma is within the range of 50 to 100 ng/ml.

Half-life of Mexiprim and average time of drug retention in the body are 4.7-5.0 hours and 4.9-5.2 hours respectively.

Mexiprim in humans is extensively metabolized to form its glucuron-conjugated product.

On average over 12 hours 0.3% of unchanged drug and 50% as glucuronoconjugate of the administered dose are excreted with urine.

Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after drug administration.

Indicators of urinary excretion of Mexiprim and its conjugated metabolite have significant individual variability.

Indications

Active ingredient

Composition

Composition per 1 ml:

Ethylmethylhydroxypyridine succinate – 50 mg

Water for injection – up to 1 ml.

How to take, the dosage

Interaction

Compatible with psychotropic drugs.

It increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), anti-Parkinsonian drugs (levodopa), reduces the toxic effects of ethyl alcohol.

Special Instructions

The degree of restriction is determined by individual tolerance of the drug.

During treatment, caution should be exercised when driving motor vehicles and engaging in other potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

Synopsis

Contraindications

Side effects

Overdose

Symptoms: sleep disturbance (insomnia, in some cases drowsiness).

Treatment: usually not required – symptoms disappear on their own within 24 hours.

In severe cases of insomnia, it is recommended to take sleeping pills.

Similarities